Proponents say recent technology advances enable a more precise administration of the treatment compared to the first device marketed, which was approved by the Food and Drug Administration in 2002.
If we were to add biological and genetic information to the equation along with recent statistical advances in forecasting predictions about reoffending would become significantly more accurate.